EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐ CD19 CAR ‐T Cells

Yushu Mao, Xiaodan Wang, Chun-Hui Jin, Zhifeng Wei, Qinghao Ding, Ke-Ke Zhang, Bo-Wen Dong, Kai-Wen Zheng, Yufei Hou, Tao Zhang, Wen-Jie Zhao, Zheng Hu iD und 1 weitere

Cancer Science · 2025

DOI: 10.1111/cas.70313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Yushu Mao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, Chin…. Hauptthemen laut MEDLINE: Receptors, CXCR4, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Human Resource and Social Security Department of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T (CAR‐T) cell therapy has demonstrated remarkable success in treating hematological malignancies; however, antigen‐positive relapse remains a significant obstacle to achieving sustained remission in B‐cell acute lymphoblastic leukemia (B‐ALL). To enhance the therapeutic efficacy of anti‐CD19 CAR (CAR19)‐T cells, we overexpressed CXCR4 in CAR19‐T cells to improve their trafficking to bone marrow (BM), a key sanctuary for minimal residual disease. We engineered CAR19‐T cells with overexpression of wild‐type CXCR4 (CAR19/CXCR4 WT ‐T) or gain‐of‐function CXCR4 S338X mutant (CAR19/CXCR4 S338X ‐T). Both CAR19/CXCR4 WT ‐T and CAR19/CXCR4 S338X ‐T cells exhibited enhanced CXCR4 surface expression in vitro and in vivo compared to control CAR19‐T cells, with the latter showing significantly superior improvements under all tested conditions, including engagement with CAR‐specific antigens or CXCR4 ligand CXCL12. Upon engagement with CXCL12, CAR19/CXCR4 S338X ‐T cells, but not CAR19/CXCR4 WT ‐T cells, displayed significantly increased activation of ERK1/2 and AKT signaling pathways, as well as elevated transcription of TNF‐α, IFN‐γ, granzyme B, CDK6, and BCL2A1, along with strengthened effector functions, chemotaxis, and activation of anti‐apoptotic pathways. Furthermore, CAR19/CXCR4 S338X ‐T cells demonstrated significantly improved migration to and retention in the BM accompanied by increased CD45RA + CCR7 + memory T cell populations, which correlated with enhanced anti‐leukemic effects following injection into B‐ALL‐bearing mice. This study offers a potentially effective strategy to improve the functionality and durability of CAR‐T cell responses in hematological malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR4Receptors, Chimeric AntigenImmunotherapy, AdoptiveAntigens, CD19T-LymphocytesAnimalsMiceHumansXenograft Model Antitumor AssaysCell Line, TumorChemokine CXCL12Female

Stichwörter der Autor:innen

B‐cell acute lymphoblastic leukemiaCXCR4 S338Xbone marrowchimeric antigen receptorminimal residual disease

Substanzen

Receptors, CXCR4Receptors, Chimeric AntigenAntigens, CD19CXCR4 protein, humanChemokine CXCL12

Autor:innen und Institutionen

  • Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, the First Hospital of Jilin University, Changchun, Jilin, China.
  • National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Jilin University, Changchun, Jilin, China.
  • International Center of Future Science, Jilin University, Changchun, Jilin, China.
  • Department of Hematology, the First Hospital of Jilin University, Changchun, Jilin, China.

ORCID-Profile: Zheng Hu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Human Resource and Social Security Department of Jilin Province
  • Science and Technology Development of Jilin Province
  • Jilin University (Bethune Medical Department)

Zitieren

APA

Mao, Y., Wang, X., Jin, C. H., Wei, Z., Ding, Q., Zhang, K. K., Dong, B. W., Zheng, K. W., Hou, Y., Zhang, T., Zhao, W. J., Hu, Z., & Yang, Y. G. (2025). Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐ CD19 CAR ‐T Cells. Cancer Science. https://doi.org/10.1111/cas.70313

Vancouver

Mao Y, Wang X, Jin CH, Wei Z, Ding Q, Zhang KK, et al. Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐ CD19 CAR ‐T Cells. Cancer Science. 2025. doi:10.1111/cas.70313

BibTeX
@article{Mao2025,
  author = {Mao, Yushu and Wang, Xiaodan and Jin, Chun-Hui and Wei, Zhifeng and Ding, Qinghao and Zhang, Ke-Ke and Dong, Bo-Wen and Zheng, Kai-Wen and Hou, Yufei and Zhang, Tao and Zhao, Wen-Jie and Hu, Zheng and Yang, Yong-Guang},
  title = {Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐ CD19 CAR ‐T Cells},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.70313}
}
Kostenlos starten →